UroGen Pharma URGN Stock
UroGen Pharma Price Chart
UroGen Pharma URGN Financial and Trading Overview
| UroGen Pharma stock price | 13.26 USD |
| Previous Close | 12.49 USD |
| Open | 12.49 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1000 |
| Day's Range | 11.89 - 13.17 USD |
| 52 Week Range | 6.16 - 16.11 USD |
| Volume | 133.5K USD |
| Avg. Volume | 194.77K USD |
| Market Cap | 288.25M USD |
| Beta (5Y Monthly) | 0.754929 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.22 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23 USD |
URGN Valuation Measures
| Enterprise Value | 328.19M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.8049536 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.2398467 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 4.827 |
| Enterprise Value/EBITDA | -4.197 |
Trading Information
UroGen Pharma Stock Price History
| Beta (5Y Monthly) | 0.754929 |
| 52-Week Change | 86.21% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 16.11 USD |
| 52 Week Low | 6.16 USD |
| 50-Day Moving Average | 11.07 USD |
| 200-Day Moving Average | 9.63 USD |
URGN Share Statistics
| Avg. Volume (3 month) | 194.77K USD |
| Avg. Daily Volume (10-Days) | 142.7K USD |
| Shares Outstanding | 23.45M |
| Float | 19.65M |
| Short Ratio | 3.42 |
| % Held by Insiders | 9.96% |
| % Held by Institutions | 69.60% |
| Shares Short | 852.1K |
| Short % of Float | 4.75% |
| Short % of Shares Outstanding | 3.62% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -164.15% |
| Operating Margin (ttm) | -116.39% |
| Gross Margin | 87.65% |
| EBITDA Margin | -115.030% |
Management Effectiveness
| Return on Assets (ttm) | -35.49% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 67.99M USD |
| Revenue Per Share (ttm) | 2.96 USD |
| Quarterly Revenue Growth (yoy) | 26.70% |
| Gross Profit (ttm) | 56.7M USD |
| EBITDA | -78203000 USD |
| Net Income Avi to Common (ttm) | -111604000 USD |
| Diluted EPS (ttm) | -4.92 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 65.05M USD |
| Total Cash Per Share (mrq) | 2.77 USD |
| Total Debt (mrq) | 100.31M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.803 |
| Book Value Per Share (mrq) | -4.972 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -89370000 USD |
| Levered Free Cash Flow (ttm) | -43794500 USD |
Profile of UroGen Pharma
| Country | United States |
| State | NJ |
| City | Princeton |
| Address | 400 Alexander Park |
| ZIP | 08540 |
| Phone | 646 768 9780 |
| Website | https://www.urogen.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 194 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Q&A For UroGen Pharma Stock
What is a current URGN stock price?
UroGen Pharma URGN stock price today per share is 13.26 USD.
How to purchase UroGen Pharma stock?
You can buy URGN shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for UroGen Pharma?
The stock symbol or ticker of UroGen Pharma is URGN.
Which industry does the UroGen Pharma company belong to?
The UroGen Pharma industry is Biotechnology.
How many shares does UroGen Pharma have in circulation?
The max supply of UroGen Pharma shares is 36.13M.
What is UroGen Pharma Price to Earnings Ratio (PE Ratio)?
UroGen Pharma PE Ratio is now.
What was UroGen Pharma earnings per share over the trailing 12 months (TTM)?
UroGen Pharma EPS is -3.22 USD over the trailing 12 months.
Which sector does the UroGen Pharma company belong to?
The UroGen Pharma sector is Healthcare.
UroGen Pharma URGN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16920.58 USD — |
-0.58
|
6.33B USD — | 16873.97 USD — | 16989.6 USD — | — - | 6.33B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2227.56 USD — |
-0.91
|
— — | 2210.18 USD — | 2234.21 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4311.81 USD — |
-1.19
|
— — | 4286.36 USD — | 4323.39 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 967.78 USD — |
-1.12
|
— — | 964.91 USD — | 969.79 USD — | — - | — — |
- {{ link.label }} {{link}}